Gary Hattersley Sells 100,000 Shares of Nuvation Bio (NYSE:NUVB) Stock

Nuvation Bio Inc. (NYSE:NUVB) insider Gary Hattersley sold 100,000 shares of the stock in a transaction on Monday, October 27th. The shares were sold at an average price of $5.02, for a total transaction of $502,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Nuvation Bio Price Performance

Shares of Nuvation Bio stock opened at $5.15 on Friday. The company has a debt-to-equity ratio of 0.13, a current ratio of 9.39 and a quick ratio of 9.38. Nuvation Bio Inc. has a fifty-two week low of $1.54 and a fifty-two week high of $5.55. The firm has a fifty day moving average price of $3.59 and a two-hundred day moving average price of $2.70. The company has a market cap of $1.76 billion, a PE ratio of -8.17 and a beta of 1.48.

Nuvation Bio (NYSE:NUVB) last released its quarterly earnings data on Thursday, August 7th. The company reported ($0.17) EPS for the quarter, hitting analysts’ consensus estimates of ($0.17). The company had revenue of $4.83 million during the quarter, compared to the consensus estimate of $0.42 million. Nuvation Bio had a negative net margin of 1,413.43% and a negative return on equity of 46.14%. Analysts expect that Nuvation Bio Inc. will post -0.36 EPS for the current year.

Institutional Trading of Nuvation Bio

Hedge funds and other institutional investors have recently modified their holdings of the stock. Millennium Management LLC grew its position in shares of Nuvation Bio by 52.4% during the 1st quarter. Millennium Management LLC now owns 3,774,003 shares of the company’s stock worth $6,642,000 after buying an additional 1,298,131 shares during the period. Natixis acquired a new stake in shares of Nuvation Bio during the 2nd quarter worth approximately $1,766,000. Marshall Wace LLP acquired a new stake in shares of Nuvation Bio during the 2nd quarter worth approximately $1,699,000. Geode Capital Management LLC grew its position in shares of Nuvation Bio by 16.8% during the 2nd quarter. Geode Capital Management LLC now owns 5,994,798 shares of the company’s stock worth $11,691,000 after buying an additional 864,194 shares during the period. Finally, AWM Investment Company Inc. acquired a new stake in shares of Nuvation Bio during the 1st quarter worth approximately $1,144,000. Institutional investors and hedge funds own 61.67% of the company’s stock.

Analyst Ratings Changes

NUVB has been the subject of a number of analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Nuvation Bio in a research note on Wednesday, October 8th. Royal Bank Of Canada lifted their price target on shares of Nuvation Bio from $6.00 to $7.00 and gave the company an “outperform” rating in a report on Friday, August 8th. HC Wainwright reissued a “buy” rating and set a $10.00 price target on shares of Nuvation Bio in a report on Friday, September 19th. Jefferies Financial Group initiated coverage on shares of Nuvation Bio in a report on Tuesday, September 30th. They set a “buy” rating and a $10.00 price target for the company. Finally, Wall Street Zen raised shares of Nuvation Bio from a “sell” rating to a “hold” rating in a report on Sunday, August 17th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $7.86.

About Nuvation Bio

Nuvation Bio Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer.